BERKELEY, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced that Deborah Smeltzer, Vice President, Operations and CFO, will present an overview of the company at the UBS Global Life Sciences conference, September 26, 2006 at 4:00 p.m. Eastern, in New York City. The webcast presentation may be accessed by visiting http://events.streamx.us/US/event/EventDetails.aspx?id=ubs20060925 .
The presentation may also be accessed by visiting the Dynavax website at http://www.Dynavax.com under the Investors section .
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax’s pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; and a therapy for non-Hodgkins lymphoma in Phase 2. Its preclinical asthma and COPD programs are partnered with AstraZeneca.
Funding for the company’s other preclinical programs in cancer, hepatitis B and hepatitis C therapies, and for an influenza vaccine have been provided by Symphony Dynamo and NIH, but represent future partnering opportunities.
Dynavax Technologies Corporation
CONTACT: Shari Annes, Corporate Communications of Dynavax TechnologiesCorporation, +1-650-888-0902, or sannes@dvax.com
